Hey Snackers,
On this day in 1945: Soviet troops liberated Auschwitz, the largest Nazi concentration and extermination camp where 1M Jews were murdered. On Holocaust Remembrance Day, we're remembering the millions of lives taken by hate — and our responsibility to oppose intolerance and genocide around the world today.
Stocks dipped yesterday, slipping from Monday's tech-driven record highs.
GameStop stock pop... Hard to say 5X fast, but even harder to explain. ICYMI: GameStop stock has been on a tear (yes, the same GameStop that you visited at the mall 15 years ago). Shares have surged over 1,000% since December, and nearly doubled in value just yesterday. And it's probably not driven by the fundamentals — aka: financial info like sales growth that you see in earnings.
Why... The momentum started around the time that former Chewy CEO Ryan Cohen (and two of his Chewy pals) announced they were joining GameStop's board. Their ecommerce expertise could help make GameStop less mall-retailer, more digital shop. But the surge goes way beyond that...
Cyberbulling is based on momentum... And while all investing carries risk, investments driven by cyberbulling can be dangerous. People riding the community-driven momentum could make significant gains, but as soon as the surge ends their investments could plunge very quickly. And unless the companies being "cyberbulled" eventually show strong fundamentals, it's likely that their shares will fall back down to earth.
"Tortoise and the Hare" vibes... In the race for a Covid-19 vaccine, there are two winners (so far). First came Pfizer and BioNTech's vaccine: the first to gain emergency use authorization in the US — and the first mRNA vaccine ever green-lit for human use. Four days later, Moderna's mRNA vax crossed the authorization finish line. Johnson & Johnson lagged behind, still in trials with its OG vaccine (read: not mRNA). But that could change...
Slow and steady wins the race?... If J&J's vax moves forward, it could have an outsize impact on the overall US rollout — which (so far) has been slow. Just over 44M doses have been distributed, and barely 1% of Americans have been fully vaccinated. Here's why J&J could speed things up:
The prize might not be financial... The J&J vaccine could be a game-changer for the world, but it probably won't be one for J&J's wallet (or its stock). Unlike Moderna and Pfizer, which are selling their vaccines for profit, J&J has pledged to sell the vaccine "at cost" (no profit). Also: J&J is already a massive company that brought in ~$83B in sales and ~$15B in profit last year — a Covid vaccine might not make a huge difference. Meanwhile, it's Moderna's first (and only) product. That could be why Moderna's stock is up ~570% over the past year, while J&J's is up just 15%.